ProCE Banner Activity

CME

Histology-Agnostic Therapies for Solid Tumors: Experts Answer Frequently Asked Questions

Clinical Thought

In this commentary, experts answer questions asked by the audience during a live symposium in June 2023 about testing for histology-agnostic biomarkers and optimal integration of these therapies into the management of solid tumors.

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: July 31, 2023

Expiration: July 30, 2024

No longer available for credit.

Share

Faculty

Chul Kim

Chul Kim, MD, MPH

Associate Professor
Department of Medicine, Division of Hematology and Oncology
Georgetown Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

John Marshall

John Marshall, MD

Medstar Hematology/Oncology
Director, Ruesch Center for Cure of GI Cancers
Lombardi Comprehensive Cancer Center Georgetown University
Washington, DC

Sapna P. Patel

Sapna P. Patel, MD

Chair, SWOG Melanoma Committee
SWOG Cancer Research Network
Associate Professor, Director of the Uveal Melanoma Program
The University of Texas MD Anderson Cancer Center
Houston, Texas

Neil H. Segal

Neil H. Segal, MD, PhD

Research Director
Associate Attending, Gastrointestinal Oncology Service
Division of Gastrointestinal Oncology
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
Cornell University
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Aadi Bioscience, Bayer HealthCare Pharmaceuticals Inc., and Lilly.

Aadi Bioscience

Bayer HealthCare Pharmaceuticals Inc.

Lilly

Program Learning Goal

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with cancer.

Goal
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to apply practice-changing clinical data and expert recommendations to optimally integrate histology-agnostic therapies into treatment of eligible patients with cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions, mutations, and other targetable genomic alterations in patients with malignant solid tumors

  • Appraise emerging clinical efficacy and safety data supporting the use of histology-agnostic therapies in solid tumors

  • Formulate strategies for integrating histology-agnostic agents into the management of eligible patients with cancer based on biomarker assessment, current evidence as well as expert and guideline recommendations

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

John Marshall, MD

Medstar Hematology/Oncology
Director, Ruesch Center for Cure of GI Cancers
Lombardi Comprehensive Cancer Center Georgetown University
Washington, DC

John Marshall, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Caris, Daiichi, Merck, Pfizer, Seagen, Taiho; Chief Medical Officer: Indivumed; advisory board: OnDose, 2Curex.

Primary Author

Chul Kim, MD, MPH

Associate Professor
Department of Medicine, Division of Hematology and Oncology
Georgetown Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Chul Kim, MD, MPH: consultant/advisor/speaker: Arcus, AstraZeneca, Daiichi Sankyo, Diffusion, Eisai, Janssen, Jazz, Mirati, Novartis, PierianDX, Regeneron, Sanofi; researcher: AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Debiopharm, Genentech, Janssen, Karyopharm, Lyell Immunopharma, Merck, Novartis, Regeneron.

Sapna P. Patel, MD

Chair, SWOG Melanoma Committee
SWOG Cancer Research Network
Associate Professor, Director of the Uveal Melanoma Program
The University of Texas MD Anderson Cancer Center
Houston, Texas

Sapna P. Patel, MD: consultant/advisor/speaker: Bristol-Myers Squibb, Cardinal Health, Castle Biosciences, Delcath, Guidepoint Global, Hexal/Sandoz, Immatics, Immunocore, Novartis, OncoSec, Pfizer, Replimune, Terranova Medica, TriSalus Life Sciences; researcher: Bristol-Myers Squibb, Foghorn Therapeutics, Ideaya, InxMed, Lyvgen, Novartis, Provectus, Seagen, Syntrix Bio, TriSalus Life Sciences.

Neil H. Segal, MD, PhD

Research Director
Associate Attending, Gastrointestinal Oncology Service
Division of Gastrointestinal Oncology
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
Cornell University
New York, New York

Neil H. Segal, MD, PhD: consultant/advisor/speaker: ABL Bio, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Numab, Puretech, Regeneron, Revitope, Roche/Genentech; researcher: AstraZeneca, Bristol-Myers Squibb, Immunocore, Merck, Pfizer, Puretech, Regeneron, Roche/Genentech.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from July 31, 2023, through July 30, 2024:

1. Login or Sign Up for an account by clicking at the top of this page.
2. Read the target audience, learning objectives, and faculty disclosures.
3. View and study the content in its entirety.
4. Submit answers to the evaluation questions online.

You must respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.